| scholarly article | Q13442814 |
| P356 | DOI | 10.2215/CJN.05691108 |
| P8608 | Fatcat ID | release_55gl6zdac5bf3hkztlujheveoe |
| P932 | PMC publication ID | 2758253 |
| P698 | PubMed publication ID | 19808243 |
| P50 | author | Wim Oyen | Q42976851 |
| Elena Levtchenko | Q66342517 | ||
| P2093 | author name string | Jan A M Kremer | |
| Jack F M Wetzels | |||
| Wim J G Oyen | |||
| Marije M Löwik | |||
| Henriette A C Kyrieleis | |||
| Bert L P van den Heuvel | |||
| Hans R M Cruysberg | |||
| Ilse Pronk | |||
| P2860 | cites work | Structure of the gene for congenital nephrotic syndrome of the finnish type (NPHS1) and characterization of mutations | Q24540018 |
| NPHS2 mutations in late-onset focal segmental glomerulosclerosis: R229Q is a common disease-associated allele | Q24554305 | ||
| Specific activation of the glucocorticoid receptor and modulation of signal transduction pathways in human lens epithelial cells | Q24655239 | ||
| Potassium channel and NKCC cotransporter involvement in ocular refractive control mechanisms | Q28473235 | ||
| Prediction of creatinine clearance from serum creatinine | Q29615603 | ||
| Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee | Q29619180 | ||
| Effects of dexamethasone on human lens epithelial cells in culture. | Q33354094 | ||
| Ocular complications of topical, peri-ocular, and systemic corticosteroids | Q34120572 | ||
| A formula to estimate the approximate surface area if height and weight be known. 1916. | Q34437560 | ||
| Mutation spectrum in the nephrin gene (NPHS1) in congenital nephrotic syndrome | Q34514814 | ||
| Cyclophosphamide-induced gonadal toxicity: a treatment dilemma in patients with lupus nephritis? | Q36025755 | ||
| Glucocorticoid-induced osteoporosis in children: impact of the underlying disease | Q36749026 | ||
| Genetics of focal segmental glomerulosclerosis | Q36772507 | ||
| The etiology of steroid cataract | Q36953676 | ||
| Nonenzymatic modification of lens crystallins by prednisolone induces sulfhydryl oxidation and aggregate formation: in vitro and in vivo studies | Q39318222 | ||
| NPHS2 R229Q functional variant is associated with microalbuminuria in the general population | Q39675959 | ||
| Pituitary-gonadal function in women following cyclophosphamide treatment for childhood nephrotic syndrome: long-term follow-up study | Q41933644 | ||
| A meta-analysis of cytotoxic treatment for frequently relapsing nephrotic syndrome in children | Q43588188 | ||
| Ocular complications of paediatric patients with nephrotic syndrome | Q43729890 | ||
| CBO guideline 'Osteoporosis' (second revision | Q44089446 | ||
| Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia | Q44357198 | ||
| Gonadal function in males treated with cyclophosphamide for nephrotic syndrome | Q44389212 | ||
| Growth in steroid-responsive nephrotic syndrome: a study of 85 pediatric patients. | Q44443643 | ||
| Long-term linear growth of children with severe steroid-responsive nephrotic syndrome | Q44481333 | ||
| Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome | Q45030489 | ||
| Bigenic heterozygosity and the development of steroid-resistant focal segmental glomerulosclerosis | Q45746724 | ||
| Evaluation of reproductive functions in male adolescents following renal transplantation | Q46258282 | ||
| Longitudinal follow-up of bone mineral density in children with nephrotic syndrome and the role of calcium and vitamin D supplements | Q46546927 | ||
| Children with steroid-sensitive nephrotic syndrome come of age: long-term outcome | Q46673010 | ||
| Reduced bone mineral density in adults treated with high-dose corticosteroids for childhood nephrotic syndrome | Q46749556 | ||
| Nephrin gene (NPHS1) in patients with minimal change nephrotic syndrome (MCNS). | Q47756929 | ||
| Prognostic significance of the early course of minimal change nephrotic syndrome: report of the International Study of Kidney Disease in Children. | Q53360030 | ||
| Nephrotic syndrome: from toddlers to twenties | Q69367325 | ||
| Report of the Second Task Force on Blood Pressure Control in Children--1987. Task Force on Blood Pressure Control in Children. National Heart, Lung, and Blood Institute, Bethesda, Maryland | Q69703804 | ||
| Long-term outcome for children with minimal-change nephrotic syndrome | Q69856770 | ||
| Steroid-sensitive nephrotic syndrome: from childhood to adulthood | Q73069621 | ||
| Genetic polymorphism of NPHS1 modifies the clinical manifestations of Ig A nephropathy | Q73812715 | ||
| K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease | Q80010742 | ||
| Long-term outcome after cyclophosphamide treatment in children with steroid-dependent and frequently relapsing minimal change nephrotic syndrome | Q80248543 | ||
| Ocular findings in Japanese children with nephrotic syndrome receiving prolonged corticosteroid therapy | Q83298604 | ||
| P433 | issue | 10 | |
| P921 | main subject | nephrotic syndrome | Q504790 |
| P304 | page(s) | 1593-1600 | |
| P577 | publication date | 2009-09-24 | |
| P1433 | published in | Clinical Journal of the American Society of Nephrology | Q15757929 |
| P1476 | title | Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children | |
| P478 | volume | 4 |
| Q35674857 | A series of patients with minimal change nephropathy treated with rituximab during adolescence and adulthood |
| Q88155473 | Ambulatory Blood Pressure Monitoring in Frequently Relapsing Nephrotic Syndrome |
| Q33571864 | American Society of Nephrology quiz and questionnaire 2013: glomerulonephritis |
| Q50856119 | Any value of podocyte B7-1 as a biomarker in human MCD and FSGS? |
| Q47333560 | Body weight-based prednisolone versus body surface area-based prednisolone regimen for induction of remission in children with nephrotic syndrome: a randomized, open-label, equivalence clinical trial |
| Q53702610 | Calcineurin inhibitors and nephrotoxicity in children. |
| Q87402193 | Chapter 3: Steroid-sensitive nephrotic syndrome in children |
| Q38255356 | Childhood nephrotic syndrome in the 21st century: What's new? |
| Q53625850 | Clinical practice guideline for pediatric idiopathic nephrotic syndrome 2013: medical therapy. |
| Q93044523 | Continuous B-cell depletion in frequently relapsing, steroid-dependent and steroid-resistant nephrotic syndrome |
| Q34362680 | Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome |
| Q60054138 | Efficacy and safety of rituximab in childhood-onset, difficult-to-treat nephrotic syndrome: A multicenter open-label trial in Korea |
| Q87105700 | Genetic and in vivo determinants of glucocorticoid sensitivity in relation to clinical outcome of childhood nephrotic syndrome |
| Q41808307 | Glomerular Filtration Rate Trends During Follow-up in Children With Steroid-Sensitive Nephrotic Syndrome |
| Q92816853 | Levamisole in Children with Idiopathic Nephrotic Syndrome: Clinical Efficacy and Pathophysiological Aspects |
| Q26744025 | Long-term Outcomes of Childhood Onset Nephrotic Syndrome |
| Q46912071 | Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome |
| Q33622129 | Long-term prognosis of 4 children with steroid-sensitive nephrotic syndrome and relapse after 30 years of age. |
| Q41387077 | Long-term repeated rituximab treatment for childhood steroid-dependent nephrotic syndrome |
| Q35712990 | Long-term results of children diagnosed with idiopathic nephrotic syndrome; single center experience |
| Q84070917 | Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome |
| Q38783714 | Methylprednisolone pulse therapy and intravenous cyclophosphamide therapy combined with cocktail therapy in severe pediatric Henoch-Schönlein purpura nephritis patient |
| Q40039238 | Nephrotic syndrome in infants and children: pathophysiology and management |
| Q37828086 | New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome |
| Q82686554 | Pediatrics: how 'minimal' are the adult consequences of childhood MCNS? |
| Q41906685 | REducing STEroids in Relapsing Nephrotic syndrome: the RESTERN study- protocol of a national, double-blind, randomised, placebo-controlled, non-inferiority intervention study. |
| Q37728395 | Randomised controlled trial comparing ofatumumab to rituximab in children with steroid-dependent and calcineurin inhibitor-dependent idiopathic nephrotic syndrome: study protocol |
| Q37979793 | Recurrent focal segmental glomerulosclerosis: a discrete clinical entity |
| Q57945954 | References |
| Q38543132 | Regulatory T cells and minimal change nephropathy: in the midst of a complex network |
| Q42032380 | Relationship between Angiotensin-Converting Enzyme Insertion/Deletion Gene Polymorphism and Susceptibility of Minimal Change Nephrotic Syndrome: A Meta-Analysis |
| Q39179542 | Remission of nephrotic syndrome diminishes urinary plasmin content and abolishes activation of ENaC. |
| Q53838634 | Rituximab for Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome in Adults: A Retrospective, Multicenter Study in Spain. |
| Q34683518 | Rituximab for troublesome cases of childhood nephrotic syndrome |
| Q36003160 | Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial |
| Q37275486 | Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome |
| Q85906649 | Rituximab is an efficient and safe treatment in adults with steroid-dependent minimal change disease |
| Q42723614 | Second-line options for refractory steroid-sensitive and -resistant nephrotic syndrome |
| Q82973933 | Single daily high-dose mizoribine therapy for children with steroid-dependent nephrotic syndrome prior to cyclosporine administration |
| Q37108328 | Single dose of rituximab in children with steroid-dependent minimal change nephrotic syndrome |
| Q41874959 | Study on Steroid Induced Ocular Findings in Children with Nephrotic Syndrome |
| Q92373845 | Study protocol: multicenter double-blind, randomized, placebo-controlled trial of rituximab for the treatment of childhood-onset early-stage uncomplicated frequently relapsing or steroid-dependent nephrotic syndrome (JSKDC10 trial) |
| Q51292313 | Tacrolimus for children with refractory nephrotic syndrome: a one-year prospective, multicenter, and open-label study of Tacrobell®, a generic formula. |
| Q40695800 | The amino acid mutations of the podocin in proteinuria: a meta-analysis. |
| Q37902094 | The influence of gender and sexual hormones on incidence and outcome of chronic kidney disease |
| Q50726719 | The problem of transition from pediatric to adult healthcare in patients with steroid-sensitive nephrotic syndrome (SSNS): a survey of the experts. |
| Q45762511 | Therapy of relapsing minimal-change disease in adults: a new approach? |
| Q37620681 | Tubular B7-1 expression parallels proteinuria levels, but not clinical outcomes in adult minimal change disease patients |
| Q91845232 | Urinary Epidermal Growth Factor as a Marker of Disease Progression in Children With Nephrotic Syndrome |
Search more.